RxDoctor Payments Data

Musab Nusrat, MD

Pulmonary Disease · Green Bay, WINPI 1225317399

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (46.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 92.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $8,284 and has fallen 79.9% since, to $1,663 in 2025.

$12,038in general payments, 2019–2025

Across 45 payments — averaging $267.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$11K
  • Actelion Pharmaceuticals US, Inc.$202
  • Boehringer Ingelheim$145
  • Baxter Healthcare$144
  • Insmed, Inc.$120
  • Sanofi$116
  • plus $161 from 2 others

What the payments were for

  • Travel & lodging$5,37945%
  • Food & beverage$1,0319%
  • Education$5,62847%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,038 in reported general payments places this provider in the 85th percentile of 247 pulmonary disease providers in Wisconsin.

See all pulmonary disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$76,975
Medicare patients
388
Services billed
816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter89$74,353
Spiriva RespimatTiotropium Bromide79$47,871
Breo ElliptaFluticasone/Vilanterol69$32,687
Advair HfaFluticasone Propion/Salmeterol65$32,201
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr37$27,961
SymbicortBudesonide/Formoterol Fumarate88$27,953
Stiolto RespimatTiotropium Br/Olodaterol Hcl42$26,111
Incruse ElliptaUmeclidinium Bromide41$21,549
Spiriva HandihalerTiotropium Bromide26$20,114
Combivent RespimatIpratropium/Albuterol Sulfate33$18,754
DuleraMometasone/Formoterol28$11,468
Fluticasone-SalmeterolFluticasone Propion/Salmeterol49$11,386
Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol14$7,645
Tiotropium Bromide11$7,084
Wixela InhubFluticasone Propion/Salmeterol23$6,891

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$145$92,737154 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 247 pulmonary disease providers in Wisconsin.

Other pulmonary disease in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →